       Document 0350
 DOCN  M9630350
 TI    Diverse immunological and hematological effects of interleukin 7:
       implications for clinical application.
 DT    9603
 AU    Komschlies KL; Grzegorzewski KJ; Wiltrout RH; Biological Carcinogenesis
       and Development Program, SAIC; Frederick, National Cancer
       Institute-Frederick Cancer Research; and Development Center, MD
       21702-1201, USA.
 SO    J Leukoc Biol. 1995 Dec;58(6):623-33. Unique Identifier : AIDSLINE
       MED/96107354
 AB    Interleukin-7 (IL-7) was originally discovered to be a pre-B cell growth
       factor. Soon thereafter, a broader role for IL-7 in leukocyte
       development and function began to be identified. IL-7 now has been shown
       to be a critical cytokine for normal T and B lymphopoiesis and a
       mobilizer of pluripotent stem cells and myeloid progenitors. IL-7 has
       been demonstrated to enhance T cell function and induce cytokine
       expression in monocytes. Preclinical studies have already found that
       IL-7 could accelerate murine lymphocyte regeneration following
       chemotherapy and bone marrow transplantation, induce antitumor effects
       in mice, and expand anti-HIV-specific human T cells. Thus it is
       essential that further preclinical and clinical research be performed to
       evaluate IL-7 as a potential therapy for leukopenia, bone marrow/stem
       cell transplantation, cancer, and HIV/AIDS.
 DE    Acquired Immunodeficiency Syndrome/THERAPY  Animal  Antigens,
       CD/PHYSIOLOGY  Cell Differentiation  Hematopoiesis  Human
       Interleukin-7/*PHYSIOLOGY/THERAPEUTIC USE  Mice  Neoplasms/THERAPY
       Receptors, Interleukin/PHYSIOLOGY  T-Lymphocytes/PHYSIOLOGY  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

